Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...2122232425262728293031...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Comparative analysis of plant transient expression vectors for targeted N-glycosylation. (Pubmed Central) -  Jan 10, 2023   
    Cetuximab (Cx), a therapeutic IgG1 monoclonal antibody, which carries next to the conserved Fc an additional N-glycosylation site (GS) in the Fab-domain, was used as model...Exposure to different engineering settings (encompassing stable lines and transient approaches) towards human galactosylation and sialylation resulted in Cx carrying targeted N-glycans at similar quantities using all three expression vectors. Collectively, our results exhibit the universal application of plant-based glycoengineering, thereby increasing the attractivity of the ambitious expression platform.
  • ||||||||||  Krazati (adagrasib) / BMS
    Trial completion date, Trial primary completion date, Metastases:  Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 (clinicaltrials.gov) -  Jan 9, 2023   
    P1/2,  N=822, Recruiting, 
    It could help avoiding cetuximab-induced HSR by a systematic anti-α-Gal IgE screening before treatment. Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases:  Translational analysis and final efficacy of the AVETUX trial - Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer. (Pubmed Central) -  Jan 7, 2023   
    P2
    In summary, we report the final overall survival of the AVETUX trial and propose T cell clonality and diversity as a potential marker to predict response to chemo-immunotherapy combinations in MSS mCRC by performing a central radiological review. ClinicalTrials.gov, identifier (NCT03174405).
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    PTHrP and its receptor in locally advanced laryngeal cancer, as predictors of relapse and survival () -  Jan 6, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_31;    
    HER1 and nuclear PTHrP were expressed in poorly differentiated tumors, consistently with the known up-regulation of PTHrP gene by HER1 signaling. Conclusions Our results suggest that in LALSCC nuclear PTHrP and absence of PTH1R expression could be useful in predicting response and/ or resistance to cetuximab in combined therapies, contributing to an aggressive behaviour of tumor cells downstream to HER1.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Trial primary completion date:  Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer (clinicaltrials.gov) -  Jan 6, 2023   
    P2,  N=30, Recruiting, 
    Conclusions Our results suggest that in LALSCC nuclear PTHrP and absence of PTH1R expression could be useful in predicting response and/ or resistance to cetuximab in combined therapies, contributing to an aggressive behaviour of tumor cells downstream to HER1. Trial primary completion date: Dec 2022 --> Jun 2023
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal, IO biomarker:  Novel Insights of Anti-EGFR Therapy in HNSCC: Combined with Immunotherapy or Not? (Pubmed Central) -  Jan 1, 2023   
    Anti-EGFR therapy, especially cetuximab, was validated to induce the innate and adaptive immune responses of HNSCC patients...Anti-EGFR therapy may usher in another dawn in the treatment of patients with HNSCC through combination with immunotherapy. We offer an overview of the ongoing efforts to make out the immunomodulation of the EGFR pathway in both innate and adaptive immune responses; update the constant preclinical models and clinical trials for the combination of anti-EGFR and immunotherapy in HNSCC; and finally evaluate the efficacy and advantages of the combination therapeutic strategies in clinical use.
  • ||||||||||  PK/PD data, Journal:  Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer. (Pubmed Central) -  Dec 31, 2022   
    Monoclonal antibodies have complex pharmacokinetics and pharmacodynamics, with important interactions between them. The arrival of bioequivalent molecules to the market increases the need for the characterization of pharmacokinetics and pharmacodynamics of classic monoclonal antibodies to reach bioequivalent novel molecules.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal, IO biomarker:  A review of efficacy and safety of cetuximab and bevacizumab-based monoclonal antibodies in head and neck cancer. (Pubmed Central) -  Dec 31, 2022   
    These agents are even effective in combination with other therapeutic modalities that are not being able to achieve desirable outcomes due to issues such as resistance and toxicities. Thus, newer targets as well as newer agents acting on established targets are to be explored in order to improve disease outcomes.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  CD46 protects the bladder cancer cells from cetuximab-mediated cytotoxicity. (Pubmed Central) -  Dec 28, 2022   
    Together, CD46 exhibited a cancer-protective effect against both direct (by involvement of PBMC or complement) and indirect cytotoxic activity by cetuximab in bladder cancer cells. Considering its clinical importance, CD46 could be an important link in the action mechanism of ADCC and CDC intercommunication and may be used for the development of novel therapeutic strategies.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Development of a spermine lipid for transient antibody expression. (Pubmed Central) -  Dec 24, 2022   
    Characterizations confirmed that the expressed antibody is fully functional and eligible for further research. Our study provides an effective tool for the rapid production of antibodies economically and feasibly.